# Alteplase (Activase)

Drug · id `cardio:alteplase` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Activase; tPA; Tissue plasminogen activator

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A clot-dissolving medicine given into a vein. It binds to the fibrin in a blood clot and starts to break the clot down. The US label for Activase lists three uses: acute ischemic stroke, acute heart attack, and acute massive pulmonary embolism, which means blood clots that block blood flow in the lungs.

## Technical summary

RxNorm ingredient 8410. US application BLA103172. The label record read here is effective 2026-01-20. The openFDA application record lists the original approval as submission ORIG-1 on 13 November 1987 and also covers CATHFLO ACTIVASE, a separate product that is not described here. The label also tells prescribers to rule out bleeding in the brain as the cause of stroke symptoms before treatment and gives a time limit from symptom onset; this page does not reproduce those details. This is a regulatory record, not a finding about how well the medicine works.

## Claims, with the population each applies to

## Context: United States label record for Activase (alteplase), application BLA103172

Recipient: Recipient not specified; Population: People treated for acute ischemic stroke, acute myocardial infarction or acute massive pulmonary embolism, as the label record words its three indications. The label record gives no age range in the indication text read here.; Care setting: Not stated in the label record indication text; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label record indication text; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory label)

### The US Food and Drug Administration label record for Activase (alteplase), application BLA103172, fetched on 2026-10-30, lists three indications: treating acute ischemic stroke, treating acute myocardial infarction to reduce mortality and the incidence of heart failure, and lysis of acute massive pulmonary embolism. The openFDA application record lists the original submission as ORIG-1, approved on 13 November 1987 and classified Type 1 - New Molecular Entity with priority review, and names GENENTECH as the sponsor.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: People treated for acute ischemic stroke, acute myocardial infarction or acute massive pulmonary embolism, as the label record words its three indications. The label record gives no age range in the indication text read here.; Care setting: Not stated in the label record indication text; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label record indication text; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory label)
- Limitations: A label list and an approval are regulatory facts, not findings about how well the medicine works for any person. The label text changes over time; this is the record as fetched on 2026-10-30, and the openFDA application record carries no indication text for the 1987 original approval, so the claim does not say what the medicine was first approved to treat. The stroke indication on the label record also carries a requirement to exclude intracranial hemorrhage first and a time limit from symptom onset, which this claim does not restate. The heart attack indication also carries a limitation of use on the label (the risk of stroke may outweigh the benefit in patients at low risk of death or heart failure), which this claim does not restate either. The same application also covers CATHFLO ACTIVASE, a separate product, which this claim does not cover. openFDA says not to rely on it for decisions about medical care.
- Last checked: 2026-10-30
- Sources:
  1. Supports: openFDA drug label record for ACTIVASE (alteplase): indications and usage, clinical pharmacology (Regulator, edition The openFDA drug label record returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-01-20 (effective\_time). The ACTIVASE label is a separate set from the CATHFLO ACTIVASE label, which covers central venous access devices.) <https://api.fda.gov/drug/label.json?search=set_id:%22c669f77c-fa48-478b-a14b-80b20a0139c2%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\]. Retrieved 2026-10-30T19:22:43Z. Source state: Current. Version fingerprint: 00423e9f1f06dcd6be54cdfa96cdcb4596a11109bf616e4234701a6a11f8d512.
     How it applies: The three indications on the label record.
  2. Supports: openFDA drug label record for ACTIVASE (alteplase): indications and usage, clinical pharmacology (Regulator, edition The openFDA drug label record returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-01-20 (effective\_time). The ACTIVASE label is a separate set from the CATHFLO ACTIVASE label, which covers central venous access devices.) <https://api.fda.gov/drug/label.json?search=set_id:%22c669f77c-fa48-478b-a14b-80b20a0139c2%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-10-30T19:22:43Z. Source state: Current. Version fingerprint: 00423e9f1f06dcd6be54cdfa96cdcb4596a11109bf616e4234701a6a11f8d512.
     How it applies: The application number on the label record.
  3. Supports: openFDA Drugs@FDA record for BLA103172: ACTIVASE and CATHFLO ACTIVASE (alteplase) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. The record lists the application, its products and its submissions. It does not carry indication text.) <https://api.fda.gov/drug/drugsfda.json?search=openfda.application_number:%22BLA103172%22&limit=5>
     Locator: results\[0\].application\_number. Retrieved 2026-10-30T19:22:09Z. Source state: Current. Version fingerprint: a39f161583a9ec7817df523732f44e369854b1335e975d683176dea0a65f519f.
     How it applies: The application number of the openFDA application record.
  4. Supports: openFDA Drugs@FDA record for BLA103172: ACTIVASE and CATHFLO ACTIVASE (alteplase) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. The record lists the application, its products and its submissions. It does not carry indication text.) <https://api.fda.gov/drug/drugsfda.json?search=openfda.application_number:%22BLA103172%22&limit=5>
     Locator: results\[0\].submissions\[7\].submission\_type. Retrieved 2026-10-30T19:22:09Z. Source state: Current. Version fingerprint: a39f161583a9ec7817df523732f44e369854b1335e975d683176dea0a65f519f.
     How it applies: The original submission (ORIG, number 1).
  5. Supports: openFDA Drugs@FDA record for BLA103172: ACTIVASE and CATHFLO ACTIVASE (alteplase) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. The record lists the application, its products and its submissions. It does not carry indication text.) <https://api.fda.gov/drug/drugsfda.json?search=openfda.application_number:%22BLA103172%22&limit=5>
     Locator: results\[0\].submissions\[7\].submission\_status\_date. Retrieved 2026-10-30T19:22:09Z. Source state: Current. Version fingerprint: a39f161583a9ec7817df523732f44e369854b1335e975d683176dea0a65f519f.
     How it applies: The date of the original approval, written as eight digits (year, month, day).
  6. Supports: openFDA Drugs@FDA record for BLA103172: ACTIVASE and CATHFLO ACTIVASE (alteplase) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. The record lists the application, its products and its submissions. It does not carry indication text.) <https://api.fda.gov/drug/drugsfda.json?search=openfda.application_number:%22BLA103172%22&limit=5>
     Locator: results\[0\].submissions\[7\].submission\_class\_code\_description. Retrieved 2026-10-30T19:22:09Z. Source state: Current. Version fingerprint: a39f161583a9ec7817df523732f44e369854b1335e975d683176dea0a65f519f.
     How it applies: The submission classification of the original approval.
  7. Supports: openFDA Drugs@FDA record for BLA103172: ACTIVASE and CATHFLO ACTIVASE (alteplase) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. The record lists the application, its products and its submissions. It does not carry indication text.) <https://api.fda.gov/drug/drugsfda.json?search=openfda.application_number:%22BLA103172%22&limit=5>
     Locator: results\[0\].submissions\[7\].review\_priority. Retrieved 2026-10-30T19:22:09Z. Source state: Current. Version fingerprint: a39f161583a9ec7817df523732f44e369854b1335e975d683176dea0a65f519f.
     How it applies: The review priority of the original approval.
  8. Supports: openFDA Drugs@FDA record for BLA103172: ACTIVASE and CATHFLO ACTIVASE (alteplase) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. The record lists the application, its products and its submissions. It does not carry indication text.) <https://api.fda.gov/drug/drugsfda.json?search=openfda.application_number:%22BLA103172%22&limit=5>
     Locator: results\[0\].sponsor\_name. Retrieved 2026-10-30T19:22:09Z. Source state: Current. Version fingerprint: a39f161583a9ec7817df523732f44e369854b1335e975d683176dea0a65f519f.
     How it applies: The application sponsor, as the record writes the name.
  9. Supports: openFDA Drugs@FDA record for BLA103172: ACTIVASE and CATHFLO ACTIVASE (alteplase) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. The record lists the application, its products and its submissions. It does not carry indication text.) <https://api.fda.gov/drug/drugsfda.json?search=openfda.application_number:%22BLA103172%22&limit=5>
     Locator: results\[0\].products\[0\].brand\_name. Retrieved 2026-10-30T19:22:09Z. Source state: Current. Version fingerprint: a39f161583a9ec7817df523732f44e369854b1335e975d683176dea0a65f519f.
     How it applies: The brand name of the first listed product.
  10. Background: openFDA Drugs@FDA record for BLA103172: ACTIVASE and CATHFLO ACTIVASE (alteplase) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. The record lists the application, its products and its submissions. It does not carry indication text.) <https://api.fda.gov/drug/drugsfda.json?search=openfda.application_number:%22BLA103172%22&limit=5>
     Locator: results\[0\].products\[1\].brand\_name. Retrieved 2026-10-30T19:22:09Z. Source state: Current. Version fingerprint: a39f161583a9ec7817df523732f44e369854b1335e975d683176dea0a65f519f.
     How it applies: The application also lists CATHFLO ACTIVASE, a separate product.

## Connected pages

- Listed as an indication on the US label: Ischemic stroke (`cardio:ischemic-stroke`)
- Listed as an indication on the US label: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Files under this front: Medicines (`cardio:front-medicines`)
- The US label calls alteplase a tissue plasminogen activator and its use thrombolytic therapy: Fibrinolytic (clot-dissolving) drugs (`cardio:fibrinolytic-clot-dissolving-drugs`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 14 registry trials

## Provenance

Content hash: 970a7d99134e2c3ec1d40a12361425903ed4c3c88e563c9b8bc4e5e1b2a6a29e
Last substantive edit: 2026-10-30
Evidence last checked: 2026-10-30
